US medical devices industry saw a rise of 4.60% in overall deal activity during April 2021, when compared with the last 12-month average, led by $5bn merger of CA Healthcare Acquisition and LumiraDx, according to GlobalData’s deals database.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
- Embed this chart
Embed this chart into your website
Copy and paste the image source into your website to display the chart.
A total of 91 deals worth $9.6bn were announced in April 2021, compared with the 12-month average of 87 deals.
venture financing was the leading category in the month in terms of volume with 56 deals, which accounted for 61.5% of all deals.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataIn second place was M&A with 23 deals, followed by private equity with 12 transactions, respectively accounting for 25.3% and 13.2% of overall deal activity in the US technology industry during the month.
In terms of value of deals, M&A was the leading deal category in the US medical devices industry with total deals worth $7.41bn, while venture financing and private equity deals totalled $1.42bn and $727.8m respectively.
US medical devices industry deals in April 2021: Top deals
The top five medical devices industry deals accounted for 79.8% of the overall value during April 2021.
The combined value of the top five medical devices deals stood at $7.62bn, against the overall value of $9.6bn recorded for the month.
The top five medical devices industry deals of April 2021 tracked by GlobalData were:
1) The $5bn merger of CA Healthcare Acquisition and LumiraDx
2) The $1.8bn acquisition of Luminex by DiaSorin
3) The Carlyle Group’s $435m private equity deal with Unchained Labs
4) The $200m acquisition deal with Genosity by InVitae
5) Mountain Crest AcquisitionII’s acquisition of Better Therapeutics for $187m.
